Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer

The standard of care for stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by durvalumab. Although doses higher than 66 Gy are standard in our center, they were used in only 6.9% of patients in the PACIFIC trial. We report our experience with durvalumab after high-dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Landman, Yosef, Jacobi, Oded, Kurman, Noga, Yariv, Orly, Peretz, Idit, Rotem, Ofer, Dudnik, Elizabeth, Zer, Alona, Allen, Aaron M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366536/
https://www.ncbi.nlm.nih.gov/pubmed/34408921
http://dx.doi.org/10.1080/2162402X.2021.1959979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366536/
https://www.ncbi.nlm.nih.gov/pubmed/34408921
http://dx.doi.org/10.1080/2162402X.2021.1959979

Ejemplares similares